 "remdesivir, coronavirus")
After Hetero, Cipla and Mylan, another pharmaceutical major Jubilant Generics Ltd, Uttar Pradesh was given permission by India's drug regulator on Monday to manufacture and market anti-viral drug Remdesivir for "restricted emergency use" on hospitalised Covid-19 patients, official sources told PTI.
Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.
On June 21, Hetero and Cipla and on July 2 Mylan were given permission to manufacture and market the drug on the same conditions.
The Union Health Ministry in its
